Business Description
Bioage Labs Inc
NAICS : 325411
SIC : 2836
ISIN : US09077V1008
Description
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 32.75 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.15 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.9 | |||||
| 9-Day RSI | 49.5 | |||||
| 14-Day RSI | 44.49 | |||||
| 3-1 Month Momentum % | -74.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.63 | |||||
| Quick Ratio | 17.63 | |||||
| Cash Ratio | 17.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -12.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -40.12 | |||||
| ROIC % | -337.95 | |||||
| ROC (Joel Greenblatt) % | -10000.9 | |||||
| ROCE % | -44.08 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.49 | |||||
| Price-to-Tangible-Book | 0.49 | |||||
| EV-to-EBIT | 2.55 | |||||
| EV-to-EBITDA | 2.56 | |||||
| EV-to-FCF | 3.09 | |||||
| Price-to-Net-Current-Asset-Value | 0.49 | |||||
| Price-to-Net-Cash | 0.49 | |||||
| Earnings Yield (Greenblatt) % | 39.22 | |||||
| FCF Yield % | -34.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BIOA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bioage Labs Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -8.519 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 44.49 | ||
| 14-Day ATR ($) | 0.332339 | ||
| 20-Day SMA ($) | 4.4465 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 3.85 - 26.62 | ||
| Shares Outstanding (Mil) | 35.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioage Labs Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioage Labs Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bioage Labs Inc Frequently Asked Questions
What is Bioage Labs Inc(BIOA)'s stock price today?
The current price of BIOA is $4.47. The 52 week high of BIOA is $26.62 and 52 week low is $3.85.
When is next earnings date of Bioage Labs Inc(BIOA)?
The next earnings date of Bioage Labs Inc(BIOA) is .
Does Bioage Labs Inc(BIOA) pay dividends? If so, how much?
Bioage Labs Inc(BIOA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers